12.07.2023
1042-CDD-3001 Marigold
A Double-blind, Randomized, Placebo-controlled Trial of Adjunctive Ganaxolone Treatment in Children and Young Adults with Cyclindependent Kinase-like 5 (CDKL5) Deficiency Disorder (CDD) Followed by Long-term Open-label Treatment
Show more12.07.2023
N01349
A multicenter, open-label, single-arm study to evaluate the pharmacokinetics, efficacy, and safety of Brivaracetam in neonates with repeated electroencephalographic seizures
Show more12.07.2023
N01269
A randomized, dose-finding and confirmatory, double-blind, placebo-controlled, parallel group multicenter study with a 2-stage adaptive design and randomized withdrawal to evaluate the efficacy, safety, and tolerability of Brivaracetam as monotherapy in patients 2 to 25 years of age with childhood absence epilepsy or juvenile absence epilepsy
Show more12.07.2023
CBAF312D2301 NEOS
A 2-year randomized, 3-arm, double-blind, non-inferiority study comparing the efficacy and safety of ofatumumab and siponimod versus fingolimod in pediatric patients with multiple sclerosis followed by an open-label extension
Show more12.07.2023
PROMISE
Multi-centre, randomised, open label pragmatic trial to compare the effectiveness and safety of interferon beta-1a (IFN beta-1a) administered weekly i.m. and glatiramer-acetate (GA) in pediatric patients affected by multiple sclerosis
Show more12.07.2023
H8H-MC-LAHV
Pediatric Options for Migraine Relief: A Randomized, Double-Blind, Placebo-Controlled Study of Lasmiditan for Acute Treatment of Migraine: PIONEER-PEDS1
Show more12.07.2023
BP41674 Tangelo
An Open-Label, Multicenter Study To Investigate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Ro7248824 In Participants With Angelman Syndrome
Show more12.07.2023
Zogenix-1900
An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy for Seizures in Patients with Rare Seizure Disorders Such as Epileptic Encephalopathies Including Dravet Syndrome and Lennox-Gastaut Syndrome
Show more12.07.2023
WA42985 Posterity
A Phase Ii, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate The Efficacy, Safety, And Pharmacokinetics Of Obinutuzumab When Given In Combination With Mycophenolate Mofetil And Corticosteroids In Adolescent Participants With Active Class Iii Or Iv Lupus Nephritis
Show more